Compare International Business Machines Corp (IBM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs GeneDx Holdings Corp — how do they compare? International Business Machines Corp trades at $234.25 (market cap $224.62B), while GeneDx Holdings Corp trades at $82.28 (market cap $2.44B). The key difference: International Business Machines Corp is far larger — about 92.1× GeneDx Holdings Corp's market cap, and International Business Machines Corp pays a 2.84% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| IBM | WGS | |
|---|---|---|
Market Cap | $224.62B | $2.44B |
Volume | 4,481,527 | — |
Sector | Technology | Technology |
52-Week High | $329.23 | $167.51 |
52-Week Low | $205.77 | $34.51 |
Enterprise Value | $281.76B | $2.48B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM trades at $233.94, down 1.0% today, as the stock navigates mixed signals. Recent earnings showed a Q2 2026 EPS miss after two consecutive beats, while revenue growth accelerated to $67.54 billion in 2025. Technical indicators show a bullish overall signal but bearish moving averages, with RSI levels suggesting overbought conditions. The company secured a $240 million AI deal with Together AI, but faces securities fraud investigations following a 25% stock drop earlier this year.
IBM presents a complex risk-reward profile with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus pointing to 10% upside to the $257.38 price target. However, ongoing legal investigations and increased capital expenditures creating negative cash flow pose significant near-term risks. The AI partnership momentum contrasts with concerns about IBM's competitive positioning in the rapidly evolving technology landscape.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
